# Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL

> **NCT07457177** · PHASE2 · NOT_YET_RECRUITING · sponsor: **LIANG WANG** · enrollment: 40 (estimated)

## Conditions studied

- NK T-Cell Lymphoma

## Interventions

- **DRUG:** Golidocitinib + Pegaspargase + Anti-PD-1 mAb

## Key facts

- **NCT ID:** NCT07457177
- **Lead sponsor:** LIANG WANG
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-10
- **Primary completion:** 2028-01-30
- **Final completion:** 2030-01-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07457177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07457177, "Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07457177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*